Body mass index, blood pressure, and mortality from stroke: a nationally representative prospective study of 212,000 Chinese men.

PubWeight™: 1.63‹?› | Rank: Top 4%

🔗 View Article (PMID 18239175)

Published in Stroke on January 31, 2008

Authors

Maigeng Zhou1, Alison Offer, Gonghuan Yang, Margaret Smith, Gei Hui, Gary Whitlock, Rory Collins, Zhengjing Huang, Richard Peto, Zhengming Chen

Author Affiliations

1: Disease Surveillance Points Central Office, Chinese Center for Disease Control, Beijing, People's Republic of China.

Associated clinical trials:

The Benefit of Add On DLBS1033 for Ischemic Stroke Patient | NCT04425590

Articles by these authors

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (2009) 26.09

Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83

Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ (2004) 24.88

Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 17.34

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27

Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med (2013) 13.92

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 13.69

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet (2011) 13.10

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 12.92

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet (2009) 11.81

Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58

A nationally representative case-control study of smoking and death in India. N Engl J Med (2008) 10.21

Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet (2010) 10.21

Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med (2014) 9.25

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07

Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Adult and child malaria mortality in India: a nationally representative mortality survey. Lancet (2010) 7.89

21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med (2013) 7.77

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet (2012) 7.28

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet (2013) 7.25

Vitamin A supplementation every 6 months with retinol in 1 million pre-school children in north India: DEVTA, a cluster-randomised trial. Lancet (2013) 7.04

Risk factors for suicide in China: a national case-control psychological autopsy study. Lancet (2002) 7.00

Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet (2003) 6.58

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51

Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet (2012) 6.49

Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48

Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure? Lancet (2002) 5.91

Social inequalities in male mortality, and in male mortality from smoking: indirect estimation from national death rates in England and Wales, Poland, and North America. Lancet (2006) 5.70

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63

Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60

Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA (2009) 5.32

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 5.19

Prospective study of one million deaths in India: rationale, design, and validation results. PLoS Med (2005) 5.05

10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet (2010) 4.73

Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (2016) 4.49

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46

Validation of the symptom pattern method for analyzing verbal autopsy data. PLoS Med (2007) 4.35

Randomised controlled trial to compare surgical stabilisation of the lumbar spine with an intensive rehabilitation programme for patients with chronic low back pain: the MRC spine stabilisation trial. BMJ (2005) 4.27

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet (2010) 4.23

Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol (2005) 4.21

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet (2005) 4.20

Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet (2007) 4.09

Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA (2007) 4.03

Alcohol and cause-specific mortality in Russia: a retrospective case-control study of 48,557 adult deaths. Lancet (2009) 4.01

New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79

Cidea-deficient mice have lean phenotype and are resistant to obesity. Nat Genet (2003) 3.71

Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med (2014) 3.64

Setting international standards for verbal autopsy. Bull World Health Organ (2007) 3.59

Alcohol poisoning is a main determinant of recent mortality trends in Russia: evidence from a detailed analysis of mortality statistics and autopsies. Int J Epidemiol (2008) 3.56

UK cancer survival statistics. BMJ (2010) 3.44

Analyses of cancer data from three ezetimibe trials. N Engl J Med (2008) 3.44

Prevalence of smoking in China in 2010. N Engl J Med (2011) 3.38

Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA (2010) 3.34

The way forward. Lancet (2007) 3.28

Stages of the cigarette epidemic on entering its second century. Tob Control (2012) 2.98

Population deworming every 6 months with albendazole in 1 million pre-school children in North India: DEVTA, a cluster-randomised trial. Lancet (2013) 2.95

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation (2012) 2.90

Validation of cause-of-death statistics in urban China. Int J Epidemiol (2007) 2.89

Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study. Lancet (2004) 2.86

China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol (2011) 2.82

Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries. Lancet (2004) 2.80

Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet (2006) 2.72

Cohort profile: the Kadoorie Study of Chronic Disease in China (KSCDC). Int J Epidemiol (2005) 2.70

Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'. Int J Epidemiol (2006) 2.68

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ (2006) 2.67

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J (2008) 2.65

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care (2005) 2.59

Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Intern Med (2007) 2.55

Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet (2004) 2.55

Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet (2010) 2.51

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature (2013) 2.46

Randomized clinical trials--removing unnecessary obstacles. N Engl J Med (2013) 2.43